Cargando…
Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis
Vulvovaginal candidiasis (VVC) is an extremely common cause of vaginal symptoms in women. Multiple antifungal products are available by either the oral or vaginal route, although no new drugs have become available for two decades. Given the therapeutic equivalence of the antimycotic agents and their...
Autor principal: | Sobel, Jack D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869914/ https://www.ncbi.nlm.nih.gov/pubmed/24368881 http://dx.doi.org/10.2147/PPA.S38984 |
Ejemplares similares
-
Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
por: Goje, Oluwatosin, et al.
Publicado: (2023) -
Role of Vaginal Mucosa, Host Immunity and Microbiota in Vulvovaginal Candidiasis
por: Balakrishnan, Subatrra Nair, et al.
Publicado: (2022) -
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
por: Nyirjesy, Paul, et al.
Publicado: (2021) -
Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes
por: Yano, Junko, et al.
Publicado: (2019) -
The effect of curcumin-based and clotrimazole vaginal cream in the treatment of vulvovaginal candidiasis
por: Abouali, Nilufar, et al.
Publicado: (2019)